71267-16-8

Basic information

• Product Name: 3-Chloro-N-(4-nitrophenyl)benzamide
• Synonyms: 3-Chloro-N-(4-nitrophenyl)benzamide
• CAS NO: 71267-16-8
• Molecular Formula: C₁₃H₉ClN₂O₃
• Molecular Weight: 276.678
• Mol File: 71267-16-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 367.5 °C at 760 mmHg
• Flash Point: 176 °C
• Appearance: /
• Density: 1.440
• Vapor Pressure: 1.36E-05mmHg at 25°C
• Refractive Index: 1.676
• CAS DataBase Reference: 3-Chloro-N-(4-nitrophenyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Chloro-N-(4-nitrophenyl)benzamide(71267-16-8)
• EPA Substance Registry System: 3-Chloro-N-(4-nitrophenyl)benzamide(71267-16-8)

Safety Data

• Hazardous Substances Data: 71267-16-8(Hazardous Substances Data)

Usage

General Description

3-Chloro-N-(4-nitrophenyl)benzamide is a chemical compound with molecular formula C13H9ClN2O3. It is a benzamide derivative with a chlorine atom and a nitrophenyl group attached to the benzene ring. 3-Chloro-N-(4-nitrophenyl)benzamide is often utilized in the field of medicinal and pharmaceutical research as a potential drug candidate, due to its ability to interact with biological systems and potentially modulate specific biological processes. It is also used in chemical synthesis and as a building block for creating more complex molecules. Its specific properties and applications may vary depending on the intended use, and further analysis and testing may be needed to fully understand its potential uses and effects.

InChI:InChI=1/C13H9ClN2O3/c14-10-3-1-2-9(8-10)13(17)15-11-4-6-12(7-5-11)16(18)19/h1-8H,(H,15,17)

Upstream product

• 618-46-2 m-Chlorobenzoyl chloride 
• 100-01-6 4-nitro-aniline 
• 535-80-8 3-chlorobenzoate 
• 6832-92-4 3-chloro-N-phenylbenzamide 

Downstream Products

• 123098-38-4 N-(4-aminophenyl)-3-chlorophenyl carboxamide 

Relevant articles and documents

Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments

VEGF/VEGFR-2 signaling plays a critical part in tumor angiogenesis. Inhibition of this pathway has been considered as a promising approach for cancer treatment. In this work, a series of 6,7-dimethoxy-4-anilinoquinazoline derivatives bearing diarylamide moiety were designed, synthesized and evaluated as potent inhibitors of VEGFR-2 kinase. Their in vitro antiproliferation activities against two human cancer cell lines Hep-G2 and MCF-7 have also been determined. Among them, compound 14b exhibited the most potent inhibitory activity against VEGFR-2 with IC50 value of 0.016 ± 0.002 μM and it showed the most potent antiproliferative effect against Hep-G2 and MCF-7 with IC50 values at low-micromolar range. Molecular docking studies revealed that these compounds represented by the most potent compound 14b could bind well to the ATP-binding site of VEGFR-2, which suggested that compound 14b could be a potential anticancer agent targeting VEGFR-2.

Aza-acridine compound and preparation method and application thereof

The invention discloses a method for efficiently preparing an aza-acridine compound. The structural formula of the aza-acridine compound is shown as a formula I; the preparation method comprises the following steps: adding a 2-aminoquinoline-3-methanamide compound and a solvent under an air condition, and heating to reaction temperature; after the reaction is ended, separating and purifying to obtain multisubstituted acridine derivatives shown as the following formula, wherein the reaction temperature is 100 to 200DEG C, and the reaction time is 1 to 24 hours. A synthetic method of the aza-acridine compound, disclosed by the invention, has the advantages of scientificity, reasonability, simple and easily-operated synthesis process and high synthetic yield; a product is easy to purify. The invention also relates to the aza-acridine compound which can be used for inhibiting EGFR (Epidermal Growth Factor Receptor) and SrC, a preparation method of the aza-acridine compound, activity of a drug containing the aza-acridine compound and the application of the drug. The compound is shown in a formula II and can be used for preparing an EGFR and SrC activity inhibitor and a disease treatment medicine activated and mediated by the EGFR and the SrC.

4-substituted anilinoquinazoline derivatives, and preparation method and application thereof

The invention discloses novel 4-substituted anilinoquinazoline derivatives or pharmaceutically acceptable salts thereof, or polymorphic substances, solvates or stereomers of the 4-substituted anilinoquinazoline derivatives, and a preparation method and application thereof. The 4-substituted anilinoquinazoline compounds have favorable inhibition activities for EGFR and VEGFR-2 in a biological test and have obvious effects in an in-vitro anti-human tumor cell proliferation activity test.